Plain-English translation of NCT05663515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This study is looking at whether , a medication used to treat type 2 diabetes, may be linked to pancreatic cancer. Researchers will compare medical records from thousands of European patients who started taking with those who started taking other diabetes medications. The goal is to find out if the medication is associated with any increased risk of pancreatic cancer.
Even after a medication is approved and used by patients, doctors need to watch for rare side effects that may not have been caught in earlier testing. This study exists to check whether this medication might raise the risk of pancreatic cancer in people taking it for diabetes.
You likely qualify if…
You likely don't qualify if…
This is not an active treatment study—you won't visit a clinic or take any new medication. Instead, researchers will access your existing medical records from your doctor's office or insurance company across seven European countries to look at your diabetes medication history and whether you were diagnosed with pancreatic cancer during the study period. The study covers medical records from 2006 to 2023, and your participation involves simply allowing researchers to use your anonymized data.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
Denmark
Finland
France
Norway
Spain